牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析

doi:10.3969/j.issn.1672-5069.2019.06.019

摘要/Abstract

摘要： 目的系统评价应用牛磺熊去氧胆酸联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝病（NAFLD）患者的疗效与安全性。方法全面检索CNKI、VIP、WanFang Data、CBM、PubMed、The Cochrane Library、EMbase数据库公开发表的比较牛磺熊去氧胆酸与熊去氧胆酸治疗NAFLD患者的随机对照试验（RCT）研究,采用 RevMan 5.3处理软件行Meta 分析。结果在纳入的6项RCT研究中,共计682例NAFLD患者,其中342例试验组接受牛磺熊去氧胆酸联合多烯磷脂酰胆碱治疗,340例对照组接受熊去氧胆酸联合多烯磷脂酰胆碱治疗。Meta分析结果显示,试验组总体有效率显著高于对照组[RR=1.10,95%CI（1.03,1.18）,P=0.004];试验组在降低ALT[MD=13.34,95%CI（12.20,14.48）,P<0.00001]、降低AST[MD=11.29,95%CI（5.85,16.72）,P<0.0001]、降低GGT[MD=22.54,95%CI（20.75,24.33）,P<0.00001]、降低TG[MD=0.48,95%CI（0.25,0.70）,P<0.0001]、降低LDL-C[MD=0.67,95%CI（0.51, 0.83）,P<0.00001]和降低BMI水平[MD=1.57,95%CI（1.29,1.84）,P<0.00001]和提升HDL-C水平[MD=0.23,95%CI（0.18,0.27）,P<0.00001]方面,优于对照组;试验组在降低TC水平[MD=0.30,95%CI（-0.03,0.64）,P=0.08]和不良反应发生率[RR=1.00,95%CI（0.41,2.47）,P=1.00]方面与对照组比较,无显著差异;试验组也未明显改善肝脏脂肪变程度[RR=2.2,95%CI（0.97,4.98）,P=0.06]。结论应用牛磺熊去氧胆酸联合多烯磷脂酰胆碱治疗NAFLD患者疗效较好,可以更显著地改善肝功能,降低血脂水平,但这些研究的总体水平不高。

关键词: 非酒精性脂肪性肝病, 牛磺熊去氧胆酸, 熊去氧胆酸, 治疗, Meta分析

Abstract: Objective To systematically evaluate the efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease （NAFLD）. Methods We searched CNKI,VIP,WanFang Data,CBM,PubMed,The Cochrane Library,EMbase database and retrieved randomized controlled trials （RCT） on the observation of tauro ursodesoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with NAFLD since inception of database. Meta analysis was performed by using RevMan 5.3 software. Results A total of 682 NAFLD patients were included in 6 RCT studies,and 342 in the observation group were treated by tauro ursodesoxy cholic acid and polyene phosphatidyl choline,and 340 in the control group were treated by ursodeoxycholic acid and polyene phosphatidyl choline combination. The Results showed that the overall effective rate [RR=1.10,95%CI（1.03,1.18）,P=0.004],serum ALT reduction [MD=13.34,95%CI（12.20,14.48）,P<0.00001],AST reduction [MD=11.29,95%CI（5.85,16.72）,P<0.0001], GGT reduction [MD=22.54,95%CI（20.75,24.33）,P<0.00001],TG reduction[MD=0.48,95%CI（0.25,0.70）,P<0.0001],LDL-C reduction [MD=0.67,95%CI（0.51,0.83）,P<0.00001] and BMI reduction [MD=1.57,95%CI（1.29, 1.84）,P<0.00001] as well s HDL-C elevation [MD=0.23,95%CI（0.18,0.27）,P<0.00001] in the observation group in the treatment of patients with NAFLD were significantly superior to those in the control group; however,there was no significant difference between the two groups as respect to serum TC reduction [MD=0.30,95%CI（-0.03,0.64）,P=0.08] and the incidence of adverse reactions [RR=1.00,95%CI（0.41, 2.47）,P=1.00];the improvement of hepatic steatosis was also not significantly different between the two groups [RR=2.2,95%CI（0.97,4.98）,P=0.06]. Conclusion The efficacy of tauro ursodesoxy cholic acid combined with polyene phosphatidyl choline in the treatment of patients with NAFLD is good based on the domestic studies,which might be at a low level observations.

Key words: Non-alcoholic fatty liver, Tauroursodeoxycholic acid, Ursodeoxycholic acid, Therapy, Meta-analysis

邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.

Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis[J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.

参考文献

[1] Rinella M.Nonalcoholic fatty liver disease:a systematic review. JAMA,2015,313(22):2263-2273.
[2] Diehl A,Day C.Cause,pathogenesis,and treatment of nonalcoholic steatohepatitis. N Engl J Med,2017,377(21): 2063-2072.
[3] Chalasani N,Younossi Z.The diagnosis and management of nonalcoholic fatty liver disease:practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2018,67(1):328-357.
[4] Wong V,Chan W,Chitturi S,et al.Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1:definition,risk factors and assessment. J Gastroenterol Hepatol,2018,33(1):70-85.
[5] Fiorucci S,Biagtoli M,Distrutti E.Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol Res,2018,134,289-298.
[6] Younossi Z,Koenig A,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence,and outcomes. Hepatology,2016,64(1): 73-84.
[7] Labrecque D,Abbas Z,Anania F,et al.World Gastroenterology Organisation global guidelines:nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol,2014,48(6):467-473.
[8] Ferramosca A,Di Giacomo M,Zara V.Antioxidant dietary approach in treatment of fatty liver:new insights and updates. World J Gastroenterol,2017,23(23):4146-4157.
[9] Townsend S,Newsome P.Review article:new treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther,2017,46(5):494-507.
[10] Chitturi S,Wong V.The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2:management and special groups. J Gastroenterol Hepatol 2018,33(1):86-98.
[11] 非酒精性脂肪性肝病防治指南(2018年更新版). 实用肝脏病杂志,2018,21(2):177-186.
[12] 曹荣,胡旭东,柏涛,等. 熊去氧胆酸与牛磺熊去氧胆酸联合多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较. 中国药房,2013,24(4):365-367.
[13] 李志彬,徐莎,李霞,等. 两种熊去氧胆酸辅助多烯磷脂酰胆碱对非酒精性脂肪性肝炎患者血脂、肝功能指标及影像学改善的影响. 中西医结合肝病杂志,2016,26(4):219-221.
[14] 王军,胡翠兰,王哲,等. 牛磺熊去氧胆酸联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝病患者疗效观察. 实用肝脏病杂志,2015,18(5):544-545.
[15] 夏建萍,应豪. 两种熊去氧胆酸辅助多烯磷脂酰胆碱治疗NAFLD临床比较研究. 现代实用医学,2016,28(6):741-743.
[16] 许红华. 牛磺熊去氧胆酸治疗非酒精性脂肪肝效果探讨. 中国疗养医学,2017,26(9):900-902.
[17] 周健,刘黎,黄丽雯,等. 牛磺熊去氧胆酸治疗非酒精性脂肪肝疗效观察. 实用肝脏病杂志,2014,17(1):80-81.
[18] Lebeaupin C,Vallee D,Hazari Y,et al.Endoplasmic reticulum stress signaling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol,2018,69(4):927-947.
[19] Neuschwander-Tetri B.Non-alcoholic fatty liver disease. BMC Med,2017,15(1):45.
[20] 王宇明,于乐成. 肝脏炎症及其防治专家共识. 中国实用内科杂志,2014,34(2):152-162.
[21] Okiyama W,Tanaka N,Nakajma T,et al.Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress. J Hepatol,2009,50(6):1236-1246.
[22] 李笠,梁学亚. 水飞蓟宾葡甲胺联合多烯磷脂酰胆碱治疗酒精性脂肪肝患者初步临床研究. 实用肝脏病杂志,2017,20(4): 412-415.
[23] 陈潇迪,熊全,张霹云,等. 多烯磷脂酰胆碱对大鼠非酒精性脂肪性肝病的防治作用观察. 实用肝脏病杂志,2012,15(6):548-550.
[24] Jiang Q,Liu W,Li X,et al. Detection of related substances in polyene phosphatidyl choline extracted from soybean and in its commercial capsule by comprehensive supercritical fluid chromatography with mass spectrometry compared with HPLC with evaporative light scattering detection. J Sep Sci,2016,33509(2):-357.